Giustina, Andrea
Bronstein, Marcello D.
Chanson, Philippe
Petersenn, Stephan
Casanueva, Felipe F.
Sert, Caroline
Houchard, Aude
Melmed, Shlomo
Clinical trials referenced in this document:
Documents that mention this clinical trial
Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study
https://doi.org/10.1007/s11102-019-00977-5
Funding for this research was provided by:
Ipsen
Article History
First Online: 23 July 2019
Compliance with ethical standards
:
: AG has been a consultant for Ipsen and Pfizer and has received research Grants from Ipsen and Novartis. MDB has been a consultant for Chiasma, Ipsen, and Novartis, and a speaker and Clinical Trial Investigator for Ipsen and Novartis. PC has received unrestricted research and educational Grants from Ipsen, Novartis and Pfizer (on behalf of the Service of Endocrinology and Reproductive Diseases, Hôpitaux Universitaires Paris-Sud and Association Recherche Endocrinologie Bicêtre); he has served as an investigator for clinical trials funded by Novartis, Pfizer, Ipsen, Italpharmaco, Antisense, and Chiasma and has given lectures for Ipsen, Novartis, and Pfizer (all fees and honoraria paid to his Institution or Research Association). SP has been a speaker and advisory board member for Ipsen, Novartis, and Pfizer. FFC has given lectures and acted as an advisor for Pfizer and Ipsen. SM has received research grants from and acted as an investigator for Pfizer, Ipsen, and Ono; he has also acted as a consultant for Chiasma, Ionis, and Midatech. CS and AH are employees of Ipsen.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.